R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

How the Life Sciences Innovative Manufacturing Fund can boos...

Since the turn of the decade, the pharmaceuticals industry has dealt with supply chain challenges caused by both the pandemic and global conflict.

R&D

Drug repositioning to bring forgotten assets from shelves to...

A problem very rarely spoken about is the treatments that are promising, but are not developed further.

R&D

Changing Faces – Pharma and Biotech July 2024

We’re back on track this month with Changing Faces as we look back at the month in pharma and biotech hires and – especially this month – departures.

R&D

Globe showing the African continent in focus in young hands

Not if, but when: Pandemic preparedness is crucial

On Wednesday 14th August, the World Health Organization (WHO) declared that the rapidly emerging mpox outbreak in Africa had become a public health emergency of international concern (PHEIC

R&D

Longevity: Anti-ageing drugs, watch out, here we come…

Advances in multi-omics, artificial intelligence (AI), deep learning (DL), ageing biomarkers, precision imaging, ageing clocks, robotics, and smart technologies have enabled researchers to

R&D